Table 2

Distribution of individuals and ORs of cancer according to EPHX1 genotypes and predicted mEH activity

GenotypeOral/pharyngeal cancer patients (n = 121)Laryngeal cancer patients (n = 129)Control individuals (n = 172)
n (%)ORa (95% CI)n (%)ORa (95% CI)n (%)
Exon 3 genotypes
wt3/wt3b 66 (54.5)1 (Reference)72 (55.8)1 (Reference)64 (37.2)
wt3/slow 32 (26.5)0.4 (0.2–0.7)40 (31.0)0.4 (0.2–0.7)77 (44.8)
slow/slow 23 (19.0)0.8 (0.4–1.8)17 (13.2)0.5 (0.2–1.1)31 (18.0)
P for trend0.170.006
Exon 4 genotypes
wt4/wt4 80 (66.1)1 (Reference)84 (65.1)1 (Reference)121 (70.3)
wt4/rapid 38 (31.4)1.1 (0.6–2.0)c41 (31.8)1.0 (0.6–1.8)c49 (28.5)
rapid/rapid 3 (2.5)4 (3.1)2 (1.2)
Predicted mEH activity
Lowd42 (34.7)1 (Reference)43 (33.3)1 (Reference)85 (49.4)
Intermediatee55 (45.5)1.8 (1.0–3.3)59 (45.7)1.7 (1.0–3.1)65 (37.8)
Highf24 (19.8)2.1 (1.0–4.5)27 (20.9)2.4 (1.1–5.1)22 (12.8)
P for trend0.030.02
  • a ORs adjusted for sex-, age-, smoking-, and alcohol-related variables. Data on smoking and/or alcohol drinking were missing for six oral/pharynx cancer cases, six larynx cancer cases, and eight control individuals.

  • b wt, wild type.

  • c Due to small number of rapid/rapid genotype, ORs were calculated for combined wt4/rapid and rapid/rapid genotypes.

  • d slow/slow and wt4/wt4 genotypes, slow/slow and wt4/rapid genotypes, wt3/slow and wt4/wt4 genotypes.

  • e wt3/wt3 and wt4/wt4 genotypes, wt3/slow and wt4/rapid genotypes.

  • f wt3/wt3 and wt4/rapid genotypes, wt3/wt3 and rapid/rapid genotypes, wt3/slow and rapid/rapid genotypes.